Multiple emerging agents show promise in decreasing the burden of CIN. Use of these
therapies will reduce access disparities and will improve outcomes for patients with cancer …

Stem cell factors (SCFs) are pivotal factors existing in both soluble and membrane-bound
forms, expressed by endothelial cells (ECs) and fibroblasts throughout the body. These …

As the voice of cancer care clinicians and the patients they serve, ASCO has taken steps to
elevate awareness about biosimilar products and their use in oncology. In 2018, ASCO …

Importance The introduction of biosimilars and novel delivery devices between 2014 and
2019 may have changed the utilization of granulocyte colony-stimulating factors (G-CSF) …

Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …

Background Patients with cancer undergoing cytotoxic chemotherapy face an elevated risk
of developing serious infection as a consequence of their treatment, which lowers their white …

Multiple myeloma (MM) is the main indication for autologous stem cell transplantation
(ASCT). Novel supportive therapies (eg, granulocyte colony-stimulating factor) have …

BACKGROUND: It is unknown whether using pegfilgrastim biosimilars is cost saving in a
real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs …

Background Biosimilars reduce the burden of cost on patients and payers, and so doing,
increase access to life-saving care. However, biosimilar uptake in the US has been …

BACKGROUND: Chemotherapy-induced neutropenia increases the risk of febrile
neutropenia (FN) and infection with resultant hospitalizations, with substantial health care …